Treatment of Posttransplant Hepatocellular Carcinoma Recurrence
Emre Karakaya1, Aydincan Akdur, Ebru Ayvazoğlu Soy
1From the Department of General Surgery, Division of Transplantation, Baskent University Faculty of Medicine, Ankara, Turkey.
Objectives:
In patients who receive liver transplant to treat hepatocellular carcinoma, 10% to 15% posttransplant recurrence is observed. In the present study, we evaluated the long-term outcomes of patients who had received liver transplant for treatment of hepatocellular carcinoma.
Materials And Methods:
Of the 683 livertransplants that we performed, 72 were in response to hepatocellular carcinoma. The physical examination and laboratory and imaging results of the patients were retrospectively analyzed and recorded. The recipients were evaluated according to the Başkent criteria and divided into 2 groups: early diagnosis and late diagnosis.
Results:
Among 72 total patients in our study, 19 (26.3%) were pediatric recipients. Hepatocellular carcinoma recurred in 7 patients (9.7%; 5 adult, 2 pediatric). Except for one patient, all were in the late diagnosis group.The mean survivaltime of all patients was 137.45 ± 10 months.The mean survival in the early diagnosis group was longer than in the late diagnosis group. During follow-up, 11 patients died from recurrence and distant metastasis.
Conclusions:
In patients with hepatocellular carcinoma who received liver transplant, we found that postoperative recurrence of hepatocellular carcinoma and distant metastasis can be treated with surgery and/or with interventional radiology methods, which may improve patient survival after liver transplant.
